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Abstract
Aims To (1) explore and verify differences in the plasma proteome of white European (WE) and South Asian (SA) adults 
with normal glycaemic control (NGC) or non-diabetic hyperglycaemia (NDH) and to (2) validate these findings using a 
separate WE and SA cohort at a high risk of NDH.
Methods Mass spectrometry analysis was performed on fasted samples from 72 WE or SA men with NGC or NDH. These 
results were verified using specific biochemical assays and validated by repeating the analysis in an additional cohort of 30 
WE and 30 SA adults. Proteomic results were analysed using independent samples t test and univariate analysis. The targeted 
assay results were analysed using generalised linear models with adjustment for appropriate covariates including age, BMI, 
fasting plasma glucose, high-density lipoprotein-cholesterol, triglycerides and sex.
Results Only zinc-alpha-2-glycoprotein (ZAG) significantly differed between both ethnicities and glycaemic control groups. 
ZAG-specific biochemical assays verified the lower circulating ZAG in SAs (41.09 versus 37.07 (mg L−1); p = 0.014), but 
not the difference between NGC and NDH groups (p = 0.539). Validation of the ethnicity difference in a separate cohort 
confirmed that, after adjustment for covariates, ZAG was lower in SAs (p = 0.018). There was no association between ZAG 
and glycaemic control in the validation cohort.
Conclusions Our analyses identified that ZAG is lower in SAs compared to WEs, but its difference between glycaemic control 
statuses was uncertain. Further research is needed to establish whether lower ZAG in SAs is associated with, or prognostic 
of, health outcomes, particularly regarding the risk of dysglycaemia.
Keywords Proteomics · Mass spectrometry · Enzyme-linked immunosorbent assay · AZGP1 · Dysglycaemia · Type 2 
diabetes mellitus
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Introduction
Type 2 diabetes mellitus (T2DM) is a chronic metabolic 
disease characterised by peripheral insulin resistance and 
inadequate relative insulin secretion, resulting in hypergly-
caemia (WHO 1994). T2DM encompasses approximately 
90% of all cases of diabetes (ADA 2002) and is preceded 
by a high-risk category termed non-diabetic hyperglycae-
mia (NDH). In NDH, blood glucose levels are elevated 
above healthy ranges, but do not meet diagnostic criteria 
for T2DM (Tabák et al. 2012). NDH not only increases an 
individual’s risk of developing T2DM, but also cardiovas-
cular disease (Danaei et al. 2006).
South Asian (SA) individuals (predominantly Indian, 
Pakistani and Bangladeshi) account for 20% of the world’s 
population and constitute the largest ethnic minority group 
within the UK (ONS 2015). SAs have more pronounced 
insulin resistance, a two to four-fold higher risk of devel-
oping T2DM, faster rates of progression from NDH to 
T2DM and a higher risk of myocardial infarction, com-
pared to white European (WE) individuals (Gholap et al. 
2011; Harding 2003; McKeigue et al. 1988; Tuomilehto 
et al. 1984). Furthermore, these occur at a younger age and 
lower body mass index (BMI) (Chiu et al. 2011). Reasons 
for this elevated risk are not fully understood, but genetic, 
epigenetic and unhealthy lifestyle practices have all been 
suggested (Sattar and Gill 2015). However, specific physi-
ological pathways that link the SA phenotype to greater 
risk of metabolic dysfunction need further elucidation 
in order to better understand mechanisms leading to an 
elevated risk of T2DM in SA communities.
Proteomic analyses are increasingly used to identify 
novel markers of disease in order to improve personalised 
medicine (Anderson 2002). Proteomics is defined as “the 
use of quantitative measurements at protein-level of gene 
expression which characterises biological processes and 
gives insight to mechanisms of the control of gene expres-
sion” (Anderson and Anderson 1998). Previous analyses 
of proteins that differ with increasing insulin resistance, 
T2DM and an increasing burden of diabetes complications 
has identified alterations in the circulating concentrations 
of several proteins, which could be contributing factors 
to disease pathophysiology (Hwang et al. 2010; Yeh et al. 
2016; Zürbig et al. 2012). However, to date, proteomics 
technologies have not been widely harnessed to aid our 
understanding ethnic health disparities. Applying such 
approaches has the potential to identify novel proteins and 
biological pathways that will enable new insight into the 
risk of metabolic dysfunction in high risk ethnic groups.
Subsequently, the aims of this study were three-fold. 
First, to explore the plasma proteome of WE and SA adults 
with normal glycaemic control (NGC) or NDH using 
discovery mass spectrometry analysis to identify novel 
proteins that may be important in elucidating why SAs 
have a high risk of metabolic disease; second, to verify 
differences between ethnicities and glycaemic control sta-
tuses using targeted biochemical assays; third, to validate 
findings in a separate cohort of WE and SA adults with a 
high risk of dysglycaemia.
Methods
ADDITION‑Leicester cohort
Data for this cross-sectional observation analysis were 
obtained using baseline samples from the ADDITION-
Leicester cohort (Webb et al. 2010), part of the interna-
tional ADDITION study (Lauritzen et al. 2000). Briefly, 
ADDITION-Leicester involved a population level diabetes-
screening programme followed by a single-blind cluster ran-
domised trial, designed to assess the cost-effectiveness and 
efficacy of intensive multi-factorial management programme 
for those with newly diagnosed T2DM. The inclusion for 
ADDITION-Leicester was WE adults aged 40–75 years 
and SA or Afro-Caribbean adults aged 25–75 years. Exclu-
sion criteria included individuals with known T2DM, any 
terminal illness with likely prognosis less than 12 months, 
females who were pregnant or lactating, or individuals with 
any psychological disorders that would hinder the ability to 
give informed consent.
Glycaemic control was established through a standard 
75 g oral glucose tolerance test taken at the baseline visit 
of the study (Diabetes-UK 2017), which was performed 
following an overnight fast and with participants having 
refrained from alcohol and strenuous physical activity for 
48-h. Impaired fasting glucose (IFG) was defined as a fast-
ing plasma glucose (FPG) concentration between 6.1 and 
6.9 mmol·L−1 and impaired glucose tolerance (IGT) was 
defined as 2-h plasma glucose (2hPG) between 7.8 and 
11.0 mmol·L−1. Those with IFG and/or IGT were defined 
as having NDH (ADA 2015).
Anthropometric measurements were performed using 
standardised procedures and by trained members of staff. 
Height was measured to the nearest 0.1 cm using a stadiom-
eter, whilst body weight (to the nearest 0.1 kg) was measured 
in light indoor clothing. These measurements were then used 
to calculate BMI (kg m2).
FPG and 2hPG levels were measured on specific clini-
cal chemistry analyser (Abbott laboratories, Maidenhead, 
UK) analyser. Fasting lipid levels were measured using 
specific biochemical assays (Dade Behring Dimension ana-
lyser, Newark, USA). Fasting Triglyceride (TG) levels were 
measured following the enzymatic hydrolysis of glycerol and 
high-density lipoprotein cholesterol (HDL-c) was measured 
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after the isolation of other non-HDL-c apolipoproteins. Glu-
cose and lipid parameters were measured on the same day, 
in the same laboratory conditions and quality control assess-
ments were conducted daily.
STAND‑UP cohort
Data for this cross-sectional observation analysis were also 
obtained using baseline samples from the STAND-UP trial 
(April 2015- March 2017; conducted at the Leicester Diabe-
tes Centre, Leicester General Hospital and the British Heart 
Foundation Glasgow Cardiovascular Research Centre, Uni-
versity of Glasgow). The methods and results of the trial 
have been reported elsewhere (Yates et al. 2018). Briefly, 
this was a multi-component randomised crossover labora-
tory investigation into the impact of breaking up prolonged 
sitting with regular bouts of five-min standing or light walk-
ing breaks on post-prandial metabolism in older WE and SA 
adults. A total of 30 WE adults and 30 SA (Indian, Pakistani, 
Bangladeshi or other) adults were included in the trial. A 
fasted plasma sample from this cohort was used for this sub-
sequent post-hoc analysis, with participants having fasted 
overnight for 12-h, avoided alcohol for two-days and vigor-
ous exercise for three days prior to the sample being drawn.
Criteria for acceptance into this study were individuals 
aged between 65 and 79 years of age, who were able to walk 
without assistance and were able to understand and com-
municate in English. Individuals were excluded from the 
study if they (1) performed purposeful exercise (determined 
at ≥ 75-min of self-reported vigorous exerciser per week), 
(2) had any psychological condition that would impair con-
sent and subsequent study participation and (3) were using 
steroids or glucose lowering therapies.
FPG measures were obtained at the beginning of each 
trial condition following an overnight fast. The values 
obtained across the three conditions were averaged and this 
value was used as a continuous measure in this analysis. 
Postprandial glucose values were obtained from a standard-
ised meal (8 kcal/kg of body weight) that had a macronutri-
ent content reflective of a typical western diet (13% protein, 
52% carbohydrate and 35% fat).
Fasting HDL-c was quantified during the familiarisa-
tion assessment (approximately two weeks prior to the first 
experimental condition). Similar to FPG, fasting TG was 
quantified at the beginning of each trial condition and the 
values averaged. All biochemical analysis was performed 
at the British Heart Foundation Glasgow Cardiovascular 
Research Centre, University of Glasgow.
Anthropometric measurements were performed using 
standard procedures by trained members of staff. Height was 
measured to the nearest 0.5 cm, whilst body weight (to the 
nearest 0.1 kg) was measured in light indoor clothing. These 
measurements were then used to calculate BMI (kg.m2).
Discovery proteomic analysis
For the present study, 72 men from the screening phase 
of ADDITION-Leicester were selected into four equal 
groups, (1) WE-NGC, (2) WE-NDH, (3) SA-NGC, and 
(4) SA-NDH. These groups were matched for age and 
BMI, and only men were selected to reduce heterogene-
ity amongst subgroups. Discovery proteomic analysis was 
performed as part of a service by Proteomic Facility, Insti-
tute of Psychiatry, Kings College London.
For the proteomics analysis, trypsin-digested albumin 
and immunoglobulin immuno-depleted samples were 
labelled with 10-plex isobaric tandem mass tags (TMT, 
Thermo Fisher Scientific) and then fractionated by isoelec-
tric focusing, before further fractionation and separated 
by reverse phase chromatography (Easy NanoLC system; 
Thermo Fisher Scientific). Samples were then delivered 
to the mass spectrometer at a flow rate of 300 nL·min−1 
over 2 h to elute peptides. Peptides were delivered by elec-
trospray into an Orbitrap Velos Pro instrument (Thermo 
Fisher Scientific) (For full process see Supplementary 
Material; Additional Proteomics Methods (Pearsey 
2020b). Raw data were processed using Proteome Dis-
coverer 1.4 and the Swiss-Prot Human Protein Database 
was searched using Mascot Algorithm version 2.2.06 to 
obtain information on protein sequence and function. The 
eight sets of 12 raw files were then processed by Multi-
Dimensional Protein Identification Technology analysis 
using Proteome Discoverer Daemon 1.4. The concentra-
tions of the identified proteins were reported as median 
normalised.
The proteins identified that significantly differed 
between ethnic groups and/or glycaemic control statues 
were explored through Cytoscape using Clue-GO appli-
cation to assess protein mechanistic pathways and pro-
tein–protein interactions. Report settings selected for 
analysis were GO Biological Process, Cellular Compo-
nents and Molecular Function. Also selected were Kyoto 
Encyclopaedia of Genes and Genomes (KEGG), REAC-
TOME pathway and interaction analysis and Wiki Path-
ways. Proteins that were either up or downregulated acted 
as the clusters, with the significance of the pathways iden-
tified being set as Probability (p)-values of ≤ 0.05. Where 
no results were returned for the criteria set in Cytoscape, 
g:Profiler (https ://biit.cs.ut.ee/gprofi ler/gost; Elixar, Esto-
nia) was used to return protein reports.
Only proteins that differed between both ethnicities (SA 
versus WE) and groups of glycaemic control status (NGC 
versus NDH) were taken forward for verification using 
targeted biochemical assays. A list of the other proteins 
identified can be seen in the Supplementary Material, with 
Rank 1 proteins being identified in all 72 samples whilst 
Rank 2 proteins were not identified in every sample.
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Targeted biochemical assay analysis
Target assay analysis was performed on the ADDITION-
Leicester cohort samples in order to verify the discovery 
proteomic findings. Subsequently, the same assay was used 
for the STAND-UP cohort samples to validate the previous 
findings. Plasma concentrations of zinc-alpha-2-glycopro-
tein (ZAG) were determined using ELISA (Oxford Biosys-
tems, Milton Park, Oxfordshire, UK), performed according 
to the manufacturer’s instructions. The analytical limit of 
detection of the assay was 0.673 mg.  L−1. Samples were 
run in duplicate and those with an intra assay coefficient of 
variation ≥ 20% were reanalysed. Different plasma aliquots 
were used from the initial discovery proteomic analysis to 




Independent samples t tests were used to compare differ-
ence between individual groups and univariate models 
were used to compare differences in identified proteins 
between all groups (WE-NGC, WE-NDH, SA-NGC and 
SA-NDH). Fisher’s Least Significant Difference (LSD) 
post-hoc analysis was employed to determine which pairs 
of means were statistically different. Univariate analysis 
was repeated adjusting for important covariates including 
age, BMI, HDL-c and TG.
Targeted assay analysis
Generalised linear models (GLMs) were used to analyse 
the data; with ZAG  (mg.  L−1) as the dependent variable 
and with ethnicity (WE or SA), glycaemic control (NGC 
or NDH) and continuous glucose measures (FPG or 2hPG) 
as independent variables. Model 1 was unadjusted, whilst 
Model 2 was adjusted for age, BMI, HDL-c, TG and eth-
nicity (for glucose models) or FPG (for ethnicity models). 
Analysis using samples from the STAND-UP cohort were 
further adjusted for sex. For the ADDITION-Leicester 
cohort, glucose was analysed both as a categorical (NGC 
vs NDH) and as a continuous variable (FPG and 2hPG). 
The relationship between ZAG and glycemic control was 
only assessed using glucose as continuous variables (FPG 
and 2hPG) within the STAND-UP cohort. HDL-c and TG 
were chosen to be included as covariates in the analysis 
because circulating levels of ZAG are thought to affect 
lipid transport (Lei et al. 2017; Zhu et al. 2014).
Significance of findings
Statistical analyses were performed using commercially 
available software (SPSS 25.0, IBM SPSS, Inc., USA). 
P-values of ≤ 0.05 were considered statistically significant 
for the proteomics analysis and targeted analyses. For the 
proteomics analyses, only proteins that were significantly 
different across the two comparisons of ethnicity and gly-
caemic control categories were selected. As this combina-
tion of significant results would occur only once every 400 
proteins by chance, correction for multiple testing was not 
undertaken. Nevertheless, the results from the proteomics 
analysis should be viewed with caution and interpreted in 
relation to the verification and validation results.
Results
Proteomic analysis of samples from a type 2 
diabetes mellitus screening trial
To explore differences in the plasma proteome of WE and 
SA individuals with NGC or NDH, bottom-up liquid chro-
matography mass spectrometry was performed on baseline 
plasma samples from 72 male participants, separated into 
four equal groups, matched for age and BMI. The median 
(IQR) age and BMI of all individuals included in this study 
were 58.5 (46.0, 67.7) years and 27.6 (25.9, 29.9) kg·m2, 
respectively. Participant characteristics for each group can 
be found in Table 1.
A total of 331 proteins were identified in the analysis, 
155 of these were identified in all samples (Rank 1). Forty-
two of these proteins differed between glycaemic control 
statuses, five of which appeared in both ethnicities (apolipo-
protein A-I, haptoglobin, Inter-alpha-trypsin inhibitor heavy 
chain H1, Serum paraoxonase/lactonase 3 and ZAG) (data 
available at Pearsey 2020c). Twenty-four proteins differed 
between ethnicities, three of which appeared in both gly-
caemic control statuses (Carboxypeptidase B2, Ig gamma-1 
chain C region and ZAG) (data available at Pearsey 2020c). 
Functional analysis identified the proteins that significantly 
differed between glycaemic control statuses as being primar-
ily involved in the regulation of immune responses, pepti-
dase activity and regulating primary and cellular metabolic 
processes including regulating protein metabolism. Simi-
larly, proteins that differed between ethnicities showed roles 
in regulating biological processes and regulating immune 
responses which includes humoral immune response. All 
proteins largely exist within the extracellular region or exist 
within the blood microparticle. A full breakdown of the pro-
teins GO terms can be found in the Supplementary Material 
(Pearsey 2020d).
263Journal of Proteins and Proteomics (2020) 11:259–268 
1 3
Only ZAG as significantly different across both groups 
of glycaemic control (fold change = 0.89; p = 0.001) and 
ethnicity (fold change = 0.90; p = 0.003), with ZAG being 
lower in NDH and SA, respectively. LSD comparisons 
showed that only the difference between WE-NDH and 
SA-NGC was not statistically different (p = 0.769) and dif-
ferences remained consistent when adjusted for age, BMI, 
HDL-c and TG (p = 0.001) (see Supplementary Fig. 1a, b) 
(data available at Pearsey 2020e). GO-annotation analysis 
of ZAG through ClueGO shows it primarily functions in 
transporter and ribonuclease activity which contributions 
to regulating peptidase (particularly hydrolase) activity, 
regulating biological and metabolic processes and acting 
in coordinating an immune response in response to a stim-
ulus. Additional reporting from CORUM (Giurgiu et al. 
2019) also shows an interaction between ZAG and prolac-
tin-inducible protein (PIP). GO-annotation analysis of the 
cellular localisation of ZAG revealed it has been located 
in the extracellular region, plasma membrane and nucleus.
Verification of samples using targeted analysis 
specific to zinc‑alpha‑2‑glycoprotein
To assess whether the results of our proteomic analyses 
could be replicated using biochemical assays specific 
to ZAG, we obtained a fresh aliquot of fasting plasma 
Table 1  Participant characteristics of the ADDITION-Leicester cohort (n = 72)
Data shown as median (inter-quartile range) or number (column percentage)
BMI body mass index, FPG fasting plasma glucose, 2hPG 2-h plasma glucose, HDL-c high-density lipoprotein cholesterol levels, TG fasting 
triglycerides
Overall (n = 72)
WE NGC (n = 18) WE NDH (n = 18) SA NGC (n = 18) SA NDH (n = 18)
Age (years) 59.00 (46.50,67.50) 59.00 (45.50,68.50) 58.00 (45.75,66.75) 59.50 (45.00,68.00)
BMI (kg·m−2) 27.77 (26.52, 29.91) 27.56 (26.99, 30.88) 26.24 (23.44, 28.86) 27.93 (26.01, 30.38)
FPG (mmol·L−1) 5.00 (4.80, 5.23) 5.45 (4.98, 6.13) 5.30 (5.08,5.43) 5.80 (5.28, 6.13)
2hPG (mmol·L−1) 4.50 (3.98, 5.33) 8.00 (7.15, 9.70) 5.10 (3.80, 5.48) 8.70 (7.43, 9.60)
HDL-c (mmol·L−1) 1.30 (1.18, 1.50) 1.20 (1.08, 1.30) 1.10 (1.08, 1.33) 1.10 (0.98, 1.30)




































































p= 0.014(a) (b) 
(c) (d) 
Fig. 1  a–d Circulating concentrations of ZAG (mg·L−1) across cat-
egories of ethnicity and glycaemic control within the ADDITION-
Leicester Cohort. Data as estimated marginal means (± S.E) for ZAG 
values (mg·L−1). Model 1: unadjusted and Model 2: adjusted for age, 
BMI, HDL-c, TG, FPG (ethnicity models) and ethnicity (glycaemic 
control models)
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belonging to the same participants selected for proteomic 
analyses (n = 68; fresh plasma aliquots were not available 
for four participants) and measured ZAG using a specific 
ELISA (Biosystems; Oxford, UK). ELISA analyses con-
firmed that circulating ZAG concentrations were higher 
in WEs compared to SA individuals (41.09 vs. 37.07 
(mg·L−1); p = 0.014; n = 68) (Fig. 1a). Differences were 
maintained after adjusting for age, BMI, FPG, HDL-c 
and TG (p = 0.020) (Fig. 1b). There were no differences 
in plasma ZAG concentrations between individuals with 
NGC and NDH (Fig. 1c, d). Similarly, in unadjusted mod-
els using the whole study population, there were no asso-
ciations between ZAG and circulating plasma glucose in 
either FPG, or 2hPG after an oral glucose tolerance test 
(Table 2). However, when models were adjusted for age, 
ethnicity, HDL-c and BMI there was a positive associa-
tion between circulating ZAG and FPG (β = 3.40 [0.45, 
6.35]; p = 0.024) (Table 2).
Validation of findings using targeted analysis 
specific to zinc‑alpha‑2‑glycoprotein
To validate the differences in ZAG between WEs and 
SAs, we performed ELISA (Biosystems; Oxford, UK) 
on samples from the STAND-UP study of older adults 
(n = 60; WE = 30, SA = 30). Participant characteristics 
can be found in Table 3.
ZAG concentrations were higher in WEs compared 
to SA individuals (51.25 vs. 46.70 mg·L−1; p = 0.089; 
n = 60) (Fig. 2a), with the difference becoming statis-
tically significant when adjusting for age, sex, BMI, 
FPG, TG and HDL-c, with ZAG being 7.28 [1.23,13.33] 
Table 2  Associations between circulating ZAG concentrations and 
FPG or 2hPG (n = 68)
Data are β-coefficients with 95% CI, presenting the difference in cir-
culating ZAG (mg·L−1) per unit difference in glucose (mmol·L−1). 
Model 1: unadjusted and Model 2: adjusted for age, ethnicity, BMI, 
HDL-c and TG
Variable Model 1 p Model 2 p
FPG 1.50 [− 1.68, 4.67] 0.355 3.40 [0.45, 6.35] 0.024
2hPG 0.27 [− 0.42, 0.96] 0.437 0.33 [− 0.32, 0.97] 0.319
Table 3  Participant characteristics of the STAND-UP cohort (n = 60)
Data shown as median (inter-quartile range), or number (column per-
centage)
BMI body mass index, FPG fasting plasma glucose, 2hPG 2-h plasma 
glucose, HDL-c high-density lipoprotein cholesterol levels, TG fast-
ing triglycerides
Overall (n = 60)
WE (n = 30) SA (n = 30)
Age (years) 71.22 (66.93, 75.25) 69.00 (66.00, 75.11)
Sex
 Male (%) 16 (53.33) 15 (50)
 Female (%) 14 (46.67) 15 (50)
BMI (kg·m−2) 26.5 (25.00, 28.30) 26.70 (23.56, 26.56)
FPG (mmol·L−1) 4.99 (4.49, 5.43) 5.25 (4.44, 5.73)
2hPG (mmol·L−1) 5.67 (4.61, 7.48) 6.34 (5.54, 8.02)
HDL-c (mmol·L−1) 1.56 (1.17, 1.90) 1.34 (1.06, 1.46)



































Fig. 2  a and b Circulating concentrations of ZAG (mg·L−1) across 
ethnicities within the STAND-UP Cohort. Data as estimated marginal 
means (± S.E) for ZAG values (mg·L−1). Model 1: unadjusted and 
Model 2: adjusted for age, FPG, BMI, HDL-c, TG and sex
Table 4  Associations between circulating ZAG concentrations and 
FPG or 2hPG (n = 60)
Data are β-coefficients with 95% CI, presenting the difference in cir-
culating ZAG (mg·L−1) per unit difference in glucose (mmol·L−1). 
Model 1: unadjusted and Model 2: adjusted for age, sex, ethnicity, 
BMI, HDL-c and TG
Variable Model 1 p Model 2 p
FPG − 1.53 [− 5.73, 2.66] 0.473 − 4.10 [− 8.75, 0.56] 0.085
2hPG − 0.14 [− 1.64, 1.36] 0.853 − 0.16 [− 1.78, 1.47] 0.848
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mg·L−1 in SAs compared to WEs (p = 0.018) (Fig. 2b). 
Neither FPG nor 2hPG were found to have an association 
with circulating ZAG in the validation cohort (Tables 4). 
Discussion
In this study, whilst discovery proteomics identified a 
number of proteins that differ between ethnicities and gly-
caemic control statuses, showing influence over a number 
of metabolic and biological processes that could contribute 
to disease risk, only plasma ZAG concentration differed 
between both. ZAG was lower in SAs compared to WEs 
and the difference remained when our proteomics analysis 
was verified in the same cohort and validated in a different 
cohort using a targeted ELISA method. In contrast, the 
lower ZAG values observed in those with higher glucose 
levels through proteomic analysis were not confirmed with 
either verification or validation.
ZAG is a 40–43 kDa adipokine that is encoded for by 
the AZGP1 gene (Hassan et al. 2008b) and is found to be 
present in the majority of body fluids (Burgi and Schmid 
1961; Rolli et al. 2007).
In particular, ZAG has a proposed role in lipid metabo-
lism within adipose tissue, exerting both autocrine and 
paracrine effects (Pelletier et al. 2013), and may have pos-
sible applications in obesity and obesity-related disease 
therapy (Severo et al. 2020). ZAGs role in lipid metabo-
lism is due to its recent categorisation as a potential lipid-
mobilizing factor (Bing et al. 2004), binding primarily to 
β-3-adrenoreceptor on the surface of adipocytes resulting 
in the conversion of adenosine triphosphate to cyclic-aden-
osine monophosphate and ultimately leading to increased 
lipolysis (Russell and Tisdale 2012).
This may have direct relevance to SAs, who have been 
shown to have reduced lipid oxidation when exercising 
(Hall et al. 2010), and elevated visceral fat, compared 
to age- and BMI-matched WEs (Sniderman et al. 2007). 
Subsequently, differences in lipid metabolism in SAs have 
been suggested to mediate the increased cardio-metabolic 
risk in SA individuals and may highlight the need to per-
form more moderate physical activity than WE individuals 
to achieve similar cardio-metabolic health profiles (Celis-
Morales et al. 2013). From the findings of this study, it 
could be hypothesised that ZAG may play a role in this 
response, although whether it actively mediates metabolic 
dysfunction through impaired lipid metabolism in SAs or 
is simply a marker of its development requires further 
investigation.
The equivocal findings for an association between ZAG 
and glycaemic control is consistent with the limited evi-
dence available to date. Our own recent systematic review 
and meta-analysis of 14 studies found that ZAG is lower 
in individuals with dysglycaemia (NDH, T2DM, meta-
bolic syndrome or poly-cystic ovary syndrome); however, 
there was a high level of heterogeneity and differences in 
ZAG disappeared when accounting for differences in BMI 
(Pearsey et al. 2020a). Outside of circulating ZAG, ZAG 
mRNA has been positively associated with glucose trans-
porter (GLUT)-4 mRNA expression in adipose tissue (Balaz 
et al. 2014) and evidence suggests that ZAG may act on 
other tissues, in particular human skeletal muscle cells, to 
aid improved glucose utilization through increased GLUT-4 
expression (Russell and Tisdale 2010). However, experimen-
tal mechanistic evidence has not consistently translated into 
evidence of an association within observational research, 
with most reporting a null associations (Ceperuelo-Mallafre 
et al. 2015, 2009; Garrido-Sanchez et al. 2012).
Our analyses have several strengths. Firstly, there have 
been limited investigations employing proteomics to 
explore populations composed of more than one ethnic 
group and, to our knowledge, very few that have directly 
compared ethnicities. Secondly, this was the first study 
to identify ZAG as a protein that significantly differed 
between ethnicities, which we have both verified and vali-
dated to reinforce our initial findings. As ZAG has been 
described in a number of disease and health disparities, 
our findings could help elucidate why SAs are at greater 
risk of certain chronic diseases compared to other ethnici-
ties, particularly WEs. This could include cardiovascular 
diseases, as ZAG is recognised to be lower in cases of cor-
onary artery disease (Liu et al. 2019) and lowered in cases 
of atherosclerosis development (Huang et al. 2019), which 
is also recognised to be more prevalent in SA individuals 
(Ghaffar et al. 2004). Finally, the inclusion of a cohort 
consisting of both males and females in the subsequent 
validation analysis ensures our findings are generalisable.
It should be acknowledged though that there are also 
certain limitations. Proteomics includes the identification 
of hundreds of proteins, which together with the limited 
sample size, could result in a type 1 error and thus explain 
the discrepancy between the results from the untargeted 
and targeted analysis for associations between ZAG and 
glycaemic control. This discrepancy could also reflect 
methodological differences between mass spectrometry 
and ELISA for ZAG quantification. This includes, but 
is not limited to, the inability for ELISA to distinguish 
protein structural variants and protein post-translational 
modifications (Nedelkov 2005) Also, the complex nature 
of plasma resulting in interactions between biological 
matrix components interfering with absolute protein quan-
tification (Gorovits et al. 2014). The results for ethnicity 
can be considered more robust as they were confirmed 
through verification (within sample) and validation (out of 
sample) targeted testing. However, it is possible that differ-
ences were due to residual confounding or confounding by 
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unmeasured factors could explain the differences observed. 
It could also be possible that differences are due to reverse 
causation (e.g. poor metabolic health in SAs acts to lower 
ZAG rather than vice-versa).
In conclusion, our findings show that circulating ZAG 
is lower in SA individuals than WE individuals, which 
should be interpreted as highlighting a novel biomarker 
that could be involved in mediating or predicting an 
increased risk of metabolic disease in SA communities. 
However, as our analysis was simply designed to high-
light possible proteins that may be important markers of 
ethnic health and considering an association between ZAG 
and glycaemic control was not confirmed, further research 
is required to assess whether ZAG is causally related to 
metabolic dysfunction in SAs.
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